Speaker: Mary Rondeau, ND, RH (AHG) In the last few years, intense interest in the pharmacokinetics and therapeutic actions of cannabidiol (CBD) has been growing. Cannabidiol is one of many cannabinoid compounds found in cannabis. It is distinctly different from tetrahydrocannabinol (THC) because it does not appear to alter consciousness or induce a "high". Growing scientific literature has demonstrated the benefits of CBD in neuropsychiatric conditions including antipsychotic, anxiolytic, anti-seizure, and anti-inflammatory effects. Studies that show benefits with minimal side effects are particularly of interest as many psychiatric medications have undesirable side effects. This presentation explores the endocannabinoid system, CBD pharmacokinetics, the effects of CBD on the nervous system, and the support in the literature for use in mental health disorders. Additionally, we investigate how CBD may help patients wean off select pharmaceuticals, and discuss drug-CBD interactions.
Related product: The PowerPoint for this recording is available here: 2021 Southwest Conference on Botanical Medicine: Conference Book Download (PDF)
| Accreditation Board | Credits | Type | Audience |
|---|---|---|---|
| Sonoran University of Health Sciences (SUHS) | 1.5 | Pharmacy | Naturopathic Doctor (ND) |
| Oregon Board of Naturopathic Medicine (OBNM) | 1.5 | Pharmacy | Naturopathic Doctor (ND) |